Ponezumab: Difference between revisions

Revision as of 20:47, 1 December 2023 editBuidhe (talk \| contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,068 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot ← Previous edit		Latest revision as of 20:01, 20 December 2023 edit undoJJMC89 bot III (talk \| contribs)Bots, Administrators3,684,692 editsm Moving Category:Pfizer brands to Category:Drugs developed by Pfizer per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands
Line 52:		Line 52:
	{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}		{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}

	]		]
	]		]
	]		]

Latest revision as of 20:01, 20 December 2023

Monoclonal antibody Pharmaceutical compound

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.

"Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
"Alzforum".

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab Romosozumab

Human	Stamulumab

Human	Abelacimab Alirocumab Ascrinvacumab Bentracimab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab Imciromab
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab Lecanemab Erenumab Fasinumab Fulranumab Opicinumab
Humanized	Bapineuzumab Crenezumab Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.